The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2013A New Pharmaceutical Target for Mono and Add-on Therapy in Parkinson’s Disease
Objective/Rationale:
We are targeting a molecule, for the first time in Parkinson’s research, that is only present in the human brain’s motor circuitry and that we believe will respond to... -
Biosample and Tissue Resource, 2013From Genetic Risk Toward Genetic Prognosis
Objective/Rationale:
The progression and prognosis of Parkinson’s disease (PD) varies considerably between individual patients — ranging from a manageable, functional decline to an aggressive course... -
Research Grant, 2014Role of LRRK2 in Dopamine Modulation of Striatal Glutamate Transmission
Objective/Rationale:
Many of the motor symptoms in Parkinson’s disease (PD) are attributed to a deficit of the neurotransmitter dopamine in the brain region called the striatum. Recent studies show... -
Therapeutic Pipeline Program, 2014Development of a mGluR4 Therapeutic for Parkinson's Disease
Study Rationale:
One of the major objectives for the development of new treatments for Parkinson’s disease is to find alternatives to the stimulation of the dopaminergic system through levodopa and... -
, 2021Evaluating Patient-reported Outcome Assessment in Early Parkinson’s Disease
Study Rationale: There are currently no validated tools for assessing functional changes in people at the earliest clinical stages of Parkinson’s disease (PD). Available approaches lack sufficient...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Evaluation of “PDRepair,” a Novel Neuroprotective and Neurorestorative Therapeutic for GBA1-associated Parkinson’s Disease
Study Rationale: Mutations in the GBA1 gene, which encodes an enzyme called GCase, is the strongest genetic risk factor for Parkinson’s Disease (PD) and most often results in the production of GCase...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.